IMO...IT's all about STRESS AND THE CNS HARM RELATED ...My Identical Twin Brother recently passed while being treated from/with AD diagnosis...he and I were on same ship (A/C) carrier and both flew in the same airplanes (USN never allowed us to fly in same plane) ...WE were OFTEN QUOTED as saying..."We SHOULD BE DEAD". (sadly) That is a very common theme in much of US Military vets . He died before his time and(IMO) stress was the real cause, even though his death cert said AD...BLAH, BLAH...tell that to his wife and kids.
At the end of the day...this is about stress treatment (IMO). Each human has to deal w/stress while each one of us has a unique BIO-Cell-DNA -capability structure. IMO, we still have a lot of CNS dots to connect but AVXL and team are on the right path.
About Insomnia and Anxiety
Insomnia - Left untreated, insomnia can affect memory and concentration, and raises health risks in many areas, such as high blood pressure, coronary heart disease, diabetes, cancer, depression. According to the CDC, about 1 out of 3 U.S. adults complain of poor sleep. Growing evidence shows that sleep deprivation can affect the buildup of beta-amyloid in the brain, a pathological link to dementia, Alzheimer’s disease, and Parkinson’s disease.[4]
Anxiety - Symptoms of anxiety characterize several neurological conditions. Anxiety is particularly common in individuals with symptoms of dementia and/or Alzheimer’s disease, especially for those patients who retain self-awareness of their condition. Anxiety can make certain symptoms of dementia worse, by affecting cognitive function such as attention, planning, organizing and decision-making.[5]
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
